220. Rapidly progressive glomerulonephritis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 2 / Drugs : 4 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathway : 1
Rapidly progressive glomerulonephritis and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
220 | Rapidly progressive glomerulonephritis | - |
30 | Distal myopathy | 1.000 |
90 | Retinitis pigmentosa | 1.000 |
13 | Multiple sclerosis/Neuromyelitis optica | 1.000 |
6 | Parkinson disease | 1.000 |
299 | Cystic fibrosis | 1.000 |
2 | Amyotrophic lateral sclerosis | 1.000 |
62 | Paroxysmal nocturnal hemoglobinuria | 1.000 |
63 | Idiopathic thrombocytopenic purpura | 1.000 |
75 | Cushing disease | 1.000 |
94 | Primary sclerosing cholangitis | 1.000 |
39 | Toxic epidermal necrolysis | 1.000 |
19 | Lysosomal storage disease | 1.000 |
35 | Pemphigus | 1.000 |
46 | Malignant rheumatoid arthritis | 1.000 |
49 | Systemic lupus erythematosus | 1.000 |
51 | Scleroderma | 1.000 |
60 | Aplastic anemia | 1.000 |
61 | Autoimmune hemolytic anemia | 1.000 |
65 | Primary immunodeficiency | 1.000 |
66 | IgA nephropathy | 1.000 |
84 | Sarcoidosis | 1.000 |
85 | Idiopathic interstitial pneumonia | 1.000 |
86 | Pulmonary arterial hypertension | 1.000 |
96 | Crohn disease | 1.000 |
98 | Eosinophilic gastrointestinal disease | 1.000 |
127 | Frontotemporal lobar degeneration | 1.000 |
222 | Primary nephrotic syndrome | 1.000 |
283 | Acquired pure red cell aplasia | 1.000 |
285 | Fanconi anemia | 1.000 |
331 | Idiopathic multicentric castleman disease | 1.000 |
53 | Sjogren syndrome | 1.000 |
271 | Ankylosing spondylitis | 1.000 |
26 | HTLV-1-associated myelopathy | 1.000 |
28 | Systemic amyloidosis | 1.000 |
162 | Pemphigoid | 1.000 |
228 | Bronchiolitis obliterans | 1.000 |
113 | Muscular dystrophy | 1.000 |
78 | Hypopituitarism | 1.000 |
74 | Prolactin secreting pituitary adenoma | 1.000 |
79 | Homozygous familial hypercholesterolemia | 1.000 |
93 | Primary biliary cholangitis | 1.000 |
38 | Stevens-Johnson syndrome | 1.000 |
50 | Dermatomyositis | 1.000 |
56 | Behcet disease | 1.000 |
107 | Juvenile idiopathic arthritis | 1.000 |
298 | Hereditary pancreatitis | 1.000 |
16 | Crow-Fukase syndrome | 1.000 |
97 | Ulcerative colitis | 1.000 |
300 | IgG4-related disease | 1.000 |
81 | Congenital adrenal hyperplasia | 1.000 |
296 | Biliary atresia | 1.000 |
164 | Oculocutaneous albinism | 1.000 |
40 | Takayasu arteritis | 1.000 |
41 | Giant cell arteritis | 1.000 |
226 | Interstitial cystitis with Hunners ulcer | 1.000 |
269 | Pyogenic arthritis | 1.000 |
42 | Polyarteritis nodosa | 1.000 |
43 | Microscopic polyangiitis | 1.000 |
45 | Eosinophilic granulomatosis with Polyangiitis | 1.000 |
95 | Autoimmune hepatitis | 1.000 |
284 | Diamond-Blackfan anemia | 1.000 |
11 | Myasthenia gravis | 1.000 |
44 | Wegener granulomatosis | 1.000 |
70 | Spinal stenosis | 1.000 |
224 | Purpura nephritis | 1.000 |
288 | Autoimmune acquired coagulation factor deficiency | 1.000 |
3 | Spinal muscular atrophy | 1.000 |
145 | West syndrome | 1.000 |
251 | Urea cycle disorder | 1.000 |
14 | Chronic inflammatory demyelinating polyneuropathy | 1.000 |
18 | Spinocerebellar degeneration | 1.000 |
205 | Fragile X syndrome related disease | 1.000 |
83 | Addison disease | 1.000 |
64 | Thrombotic thrombocytopenic purpura | 1.000 |
25 | Progressive multifocal leukoencephalopathy | 1.000 |
211 | Hypoplastic left heart syndrome | 1.000 |
257 | Hepatic glycogenosis | 1.000 |
235 | Hypoparathyroidism | 1.000 |
307 | Canavan disease | 1.000 |